Adkins D, et al. - In this multicenter, multigroup, phase 2 trial run across eight university sites in the US, researchers assessed the activity of palbociclib and cetuximab in platinum-resistant (group 1) and cetuximab-resistant (group 2) human papillomavirus (HPV)-unrelated head and neck squamous-cell carcinoma (HNSCC), focusing on the proportion of patients achieving an objective response. The treatment regimen used for all patients was: palbociclib orally (125 mg/day, on days 1–21) and intravenous cetuximab (400 mg/m² on cycle one, day 1, then 250 mg/m²once per week) in 28-day cycles. Group 1 and group 2 patients were followed for a median duration of 5.4 months and 5.5 months, respectively. Eleven (39%) of 28 evaluable patients in group 1 and five (19%) of 27 evaluable patients in group 2 achieved an objective response. Overall, promising activity outcomes were provided by palbociclib and cetuximab in patients with platinum-resistant or cetuximab-resistant HPV-unrelated HNSCC.